Global Cannabis Strategies Post-German Legalization: Exclusive Insights From Curaleaf, Gold Flora, Verano
At the Benzinga Cannabis Capital Conference in Hollywood, Florida, Constantin von der Groeben, managing director of Demecan, declared…
Top Cannabis Diversification Secrets: Industry Leaders Reveal Strategies For Success At Benzinga Conference
Discover how cannabis leaders at the Benzinga Conference drive growth through diversification. Unveil the strategies for industry success.
Cannabis Stock Gainers And Losers From April 16, 2024
GAINERS: Global Hemp Group (OTC:GBHPF) shares closed up 66.67% at $0.05 Heritage Cannabis Holding (OTC:HERTF) shares closed up…
What’s Going On With Marijuana Grower Tilray’s Stock?
Cannabis companies' stocks have rallied recently on renewed optimism that the DEA may reschedule marijuana to a Schedule III substance. Last week, FDA Commissioner Robert Califf told a House committee that there is "no reason" for the DEA to delay the rescheduling of marijuana from Schedule 1 to Schedule 3 of the Controlled Substances Act. He also suggested medical and recreational marijuana could have separate regulations.
Cannabis Banking Reform ‘Closer Than Ever,’ D.C. Insiders Tell Benzinga Conference: Cannabis ETF Spikes Tuesday
Former U.S. Sen. Cory Gardner tells the Benzinga Cannabis Capital Conference in Florida that several ranking congress members are intending to attach the SAFER Banking Act to the must-pass FAA reauthorization.
EXCLUSIVE: CEO Of This California Company Has Advice On How To Beat The Illicit Cannabis Market, Shares His Formula At Benzinga Conference
Being locked up in prison for cannabis “has to end,” said Kyle Kazan, Glass House Brands Inc.‘s (CBOE…
EXCLUSIVE: Florida On Cusp Of Adult-Use Legalization Cannabis Sales Boom, CEO Tells Benzinga Conference — ‘It’s Going To Be Huge’
'Florida has a million medical card holders, 23 million people living in the state, 130 million visitors a year — it's going to be huge,' says AYR Wellness CEO David Goubert.
IGC Pharma Says Cannabinoid-Based Drug Candidate Provides Fast Relief With Fewer Side Effects For Alzheimer’s-Associated Agitation
IGC Pharma shares encouraging interim data from Phase 2 trial of IGC-AD1 for Alzheimer's agitation. Results suggest significant reduction in agitation with minimal side effects compared to placebo.
EXCLUSIVE: Green Check, Brinks-Owned PAI Forge Partnership To Expand ATM Access For Cannabis Businesses
EXCLUSIVE: Discover how Green Check's partnership with PAI, powered by Brinks, aims to set new standards for cannabis ATM solutions.
4Front Ventures FY Revenue Drops 10% As Net Loss Increases, CEO Offers Optimistic Projections
A vertically-integrated cannabis company 4Front Ventures Corp. (CSE:FFNT) (OTCQX:FFNTF) reported its financial results for the fourth quarter and full year…